The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network.
 
Haojie Li
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Sneha Sura
Employment - Ontada/McKesson
 
Aram Babcock
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Lisa Herms
Employment - ConcertAI; McKesson
 
Jinhong Guo
Employment - Ontada/McKesson
 
Paul Conkling
Employment - Ontada/McKesson
 
Sonia Franco
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Puneet K. Singhal
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
Travel, Accommodations, Expenses - Merck
 
Ronac Mamtani
Honoraria - Flatiron Health
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Genentech/Roche; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Merck
 
Manojkumar Bupathi
Honoraria - Agendia; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Janssen; Myovant Sciences; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Exelixis
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Pfizer